Shannon Morris - 04 Mar 2026 Form 4 Insider Report for Erasca, Inc. (ERAS)

Role
Chief Medical Officer
Signature
/s/ Ebun Garner, Attorney-in-fact
Issuer symbol
ERAS
Transactions as of
04 Mar 2026
Net transactions value
-$300,760
Form type
4
Filing time
06 Mar 2026, 09:00:03 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Morris Shannon Chief Medical Officer C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO /s/ Ebun Garner, Attorney-in-fact 06 Mar 2026 0001973527

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ERAS Common Stock Options Exercise +20,000 $1.70* 20,000 04 Mar 2026 Direct F1
transaction ERAS Common Stock Sale $300,760 -20,000 -100% $15.04 0 04 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERAS Stock Option (right to buy) Options Exercise -20,000 -3.7% $0.000000* 515,800 04 Mar 2025 Common Stock 20,000 $1.70 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.